Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

Open-Label, Non-Randomized, Single-Arm, Multicenter Pilot Clinical Trial to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

FAITH-T1D/1, exploratory, Phase I, open-label, non-randomized, single-arm, multicenter clinical trial designed to evaluate the dose-dependent effects of tirzepatide on gastric emptying in adults with type 1 diabetes (T1D) and overweight or obesity.

The study will investigate tirzepatide administered once weekly as an adjunct to participants' usual insulin therapy delivered through automated insulin delivery (AID) systems. Tirzepatide will be administered subcutaneously, with gradual dose escalation from 2.5 mg up to 15 mg at four-week intervals, according to clinical tolerability and the protocol-defined dosing schedule. Its use in this population is off-label.

The study follows a longitudinal, within-subject design in which each participant serves as their own control. Gastric emptying will be assessed by gastric emptying scintigraphy using a standardized solid meal at baseline and at weeks 4, 8, 16 and 24. The primary objective is to characterize changes in gastric emptying in relation to tirzepatide dose. Secondary and exploratory objectives include evaluating metabolic and glycemic parameters, gastrointestinal symptoms, postprandial glucagon, lipidomic and metabolomic profiles, and the safety and tolerability of treatment. Continuous glucose monitoring and AID system data will also be reviewed throughout the study.

The target is 12 evaluable participants, with a maximum of 14 participants allowed to account for early withdrawals before an evaluable post-baseline assessment. The study includes a screening period, approximately 24 weeks of treatment and follow-up assessments through week 30.

Safety assessments will include treatment-emergent adverse events, gastrointestinal symptoms, hypoglycemia and diabetic ketoacidosis, as well as monitoring of tolerability during dose escalation. An independent Data and Safety Monitoring Committee is planned in accordance with the protocol.

The trial will be conducted at two Spanish hospital centers: Hospital Universitario Ramón y Cajal and Hospital Universitari i Politècnic La Fe. The study is exploratory and mechanistic; it is intended to characterize pharmacodynamic effects, estimate within-subject changes and inform the design of future confirmatory studies, rather than establish definitive clinical efficacy.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

12

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Madrid
      • Madrid, Madrid, España, 28034
        • Reclutamiento
        • Hospital Universitario Ramón y Cajal
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Written informed consent: Participants must have received information about the study design, objectives, and potential risks and must provide written informed consent to participate.
  • Ability to comply with study procedures: Ability and willingness to understand the study, comply with the required procedures, and attend all scheduled visits.
  • Age and diagnosis: Age ≥18 years and an established diagnosis of type 1 diabetes mellitus (T1D) for at least 1 year.
  • Stable automated insulin delivery (AID) treatment: Stable treatment with an AID system for at least 90 days before the baseline visit (Visit 0), with a commitment to maintain the same mode of insulin delivery and insulin throughout the study.
  • Baseline HbA1c: HbA1c between 6.3% and 10.5% at baseline.
  • Body mass index and weight stability: BMI ≥25 kg/m², with stable body weight (variation ≤5 kg) during at least the 90 days before inclusion.
  • Contraception requirements: Participants with reproductive potential must agree to use effective contraception throughout the study and for at least 6 months after the end of the study. The protocol specifies a highly effective contraceptive method plus a barrier method for participants with reproductive potential.

Exclusion Criteria:

Glycemic control and diabetes

  1. Two or more episodes requiring hospitalization for poor glycemic control (hyperglycemia or diabetic ketoacidosis [DKA]) during the 180 days before the baseline visit.

  2. One or more episodes of severe hypoglycemia requiring assistance from another person during the 90 days before baseline.

    Diabetes complications

  3. Active proliferative diabetic retinopathy, or a history of ophthalmologic treatment (photocoagulation, intravitreal injections, or vitrectomy) during the previous 6 months, or anticipated need for such treatment during the 6 months after inclusion.

    Recent cardiovascular disease

  4. Cardiovascular events during the 60 days before baseline, including:

    • Acute myocardial infarction.
    • Stroke.
    • Coronary revascularization.
    • Hospitalization for unstable angina.
    • Heart failure. Gastrointestinal disorders and motility
  5. Clinically significant gastrointestinal disorders, including diabetic gastroparesis.

  6. Previous bariatric surgery.

  7. Chronic use of medications that directly affect gastrointestinal motilityRenal function

  8. Estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m² at baseline.

    Neoplasms

  9. Active malignancy or malignancy in remission for less than 5 years.

  10. Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

    Psychiatric disorders

  11. Severe or unstable psychiatric disorders, including uncontrolled major depression, schizophrenia, bipolar disorder, or other severe psychiatric conditions, or severe mood or anxiety disorders during the previous 2 years.

    Concomitant medications

  12. Systemic glucocorticoid use for more than 14 days during the 90 days before baseline, excluding replacement therapy.

  13. Use of weight-loss medications or glucose-lowering medications other than insulin during the 90 days before baseline.

    Hypersensitivity

  14. Hypersensitivity to tirzepatide or any of its excipients.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tirzepatide

Tirzepatide with dose escalation from 2.5 mg to 15 mg.

Tirzepatide with dose escalation from 2.5 mg to 15 mg.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
To characterize the dose-dependent effect of tirzepatide (2.5-15 mg) on gastric emptying (GE) in adults with type 1 diabetes (T1D) and overweight/obesity, assessed as the within-subject change from baseline using gastric emptying scintigraphy (GES).
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24.
Baseline (Week 0) and Weeks 4, 8, 16, and 24.

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Change from baseline in gastric emptying half-time (t½)
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in the area under the gastric retention curve over 0-4 hours (AUC₀-₄h).
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in gastric retention at 2 hours (%GR-2h).
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in gastric retention at 4 hours (%GR-4h).
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in tight range (70-140 mg/dL)
Periodo de tiempo: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in range (TIR, 70-180 mg/dL)
Periodo de tiempo: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hypoglycemia
Periodo de tiempo: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hyperglycemia
Periodo de tiempo: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including glycemic variability.
Periodo de tiempo: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Correlation between dose-dependent delays in gastric emptying and improvements in postprandial glucose excursions (TIR, 70-180 mg/dL).
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
Changes in insulin requirements, including total daily insulin dose
Periodo de tiempo: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Changes in insulin requirements, including the ratio of prandial to basal insulin dose.
Periodo de tiempo: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Change in HbA1c from baseline to the end of the study.
Periodo de tiempo: Baseline (Week 0) and Week 30 (end-of-study visit).
Baseline (Week 0) and Week 30 (end-of-study visit).
Changes in body weight (kg)
Periodo de tiempo: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in body mass index (kg/m²)
Periodo de tiempo: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in waist-to-hip ratio (cm)
Periodo de tiempo: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in percentage of body fat
Periodo de tiempo: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes from baseline in postprandial glucagon concentrations
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Lipoprotein Cholesterol (mg/dL))
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Triglycerides (mg/dL))
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Particle Number (nmol/L))
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Particle Diameter (nm))
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial metabolomic profiles (Glycoprotein (μmol/L))
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial metabolomic profiles (LMWM (mmol/L))
Periodo de tiempo: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Incidence of treatment-emergent adverse events including gastrointestinal symptoms
Periodo de tiempo: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Incidence of treatment-emergent adverse events including hypoglycemia
Periodo de tiempo: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Incidence of treatment-emergent adverse events including diabetic ketoacidosis
Periodo de tiempo: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Tolerability of tirzepatide during dose escalation, assessed by the frequency of dose reductions
Periodo de tiempo: During the 24-week treatment period, through Week 24
During the 24-week treatment period, through Week 24
Tolerability of tirzepatide during dose escalation, assessed by the proportion of participants unable to reach the target dose of 15 mg
Periodo de tiempo: During the 24-week treatment period, through Week 24
During the 24-week treatment period, through Week 24

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de septiembre de 2026

Finalización primaria (Estimado)

1 de octubre de 2028

Finalización del estudio (Estimado)

1 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

13 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • FAITH-T1D/1
  • 2026-527062-72-00 (Ctis)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .